Skip to main content
. 2021 Jun 21;9(6):680. doi: 10.3390/vaccines9060680

Figure 11.

Figure 11

Effects of different commercial preparations of IVIg, which included GamaSTAN™ S/D (15–18 gm%, Lot 26NHCVI; (Talecris Biotherapeutics, Inc., Research Triangle Park, NC, USA) at dilutions 1/10 (concentration 15 mg/mL) and 1/80 (concentration 1.2 mg/mL), octagam® (6 gm%, Lot A913A8431; Octapharma Pharmazeutika) at dilutions 1/20 (concentration 3 mg/mL) and 1/80 (concentration 0.75 mg/mL), Gamunex®-C (10 gm%, Lots 26NKLG1 and 26NKLK1; Telacris) at dilutions 1/10 (concentration 10 mg/mL) and 1/80 (concentration 8 mg/mL), and mAb TFL-007a (at dilution 1/10, concentration 62.7 μg/mL; 1/80, concentration 7.84 μg/mL) on PHA-untreated cells were compared with the effect of medium alone on the proliferation of Treg cells, defined as CD4+/CD25+/Foxp3+. Note that IVIg preparations used in this study failed to upregulate Tregs, in contrast to TFL-007a, which significantly upregulated Treg cells at dilution 1/10. This figure is original but derived and modified from a previous report [48].